Oncotelic Therapeutics, Inc. (OTLC)

Oncotelic Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-1.67	-4.52	-7.9	5.09	-9.39	-9.5
Depreciation & Amortization	-	-	-	0.01	0.06	0.36
Other Amortization	0.14	0.12	0.3	1.98	1.45	1.32
Asset Writedown & Restructuring Costs	-	3.2	6.08	-12.84	-	-
Loss (Gain) From Sale of Investments	-	-	-0.01	-	-	-
Stock-Based Compensation	0.18	-	-	0.9	1.18	2.15
Provision & Write-off of Bad Debts	-	-	0	-	-	-
Other Operating Activities	0.13	0.11	0.3	2.6	1.95	2.32
Change in Accounts Payable	0.44	0.3	-0.05	0.8	0.22	0.47
Change in Other Net Operating Assets	0.06	0.05	-0.04	-0	0.08	0.07
Operating Cash Flow	-0.7	-0.74	-1.32	-1.45	-4.43	-2.81
Short-Term Debt Issued	-	0.66	1.41	0.97	3.07	0.35
Total Debt Issued	0.96	0.66	1.41	0.97	3.07	0.35
Short-Term Debt Repaid	-	-	-0.04	-	-0.5	-0.05
Total Debt Repaid	-	-	-0.04	-	-0.5	-0.05
Net Debt Issued (Repaid)	0.96	0.66	1.38	0.97	2.56	0.3
Issuance of Common Stock	-	-	-	0.16	1.97	2.93
Other Financing Activities	-	-	-0.13	-	-	-
Financing Cash Flow	0.96	0.66	1.25	1.13	4.53	3.22
Miscellaneous Cash Flow Adjustments	-0	-0	-	-	-	-
Net Cash Flow	0.26	-0.08	-0.07	-0.33	0.09	0.41
Cash Interest Paid	0.37	0.37	0.39	0.4	0.3	0.05
Cash Income Tax Paid	0	0	0	-	-	0
Levered Free Cash Flow	-1.25	-0.31	-0.58	-3.27	-4.24	-1.4
Unlevered Free Cash Flow	-0.87	0.1	-0.23	-3.39	-4.44	-1.47
Change in Working Capital	0.51	0.35	-0.09	0.8	0.31	0.54

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.